利拉鲁肽联合二甲双胍对T2DM合并肥胖患者脂代谢及微炎症反应的影响  

Effects of liraglutide combined with metformin on lipid metabolism and micro-inflammatory response in T2DM patients with obesity

作　　者：张卫欢[1] 李秋云[1] 周艳茹 刘星[1] 王倩[1] 郭智慧 杨春伟[1] 王婷婷 何桦 李晓庆[3] 王珊[4] ZHANG Wei-huan 1, LI Qiu-yun 1, ZHOU Yan-ru 1, LIU Xing 1, WANG Qian 1, GUO Zhi-hui 1, YANG Chun-wei 1, WANG Ting-ting 1, HE Hua 2, LI Xiao-qing 3, WANG Shan 4(1. Endocrinology Department, Kailuan General Hospital in Hebei Province, Tangshan, Hebei Province, 063000’2. Department of Color Ultrasound Medicine, Tangshan Maternity and Child Care Hospital in Hebei Province, Tangshan, Hebei Province, 063000;3. Department of Color Ultrasound Medicine, Kailuan General Hospital in Hebei Province, Tangshan, Hebei Province, 063000;4. Gastroenterology Department, Kailuan General Hospital in Hebei Province, Tangshan, Hebei Province, 06300)

机构地区：[1]河北省开滦总医院内分泌科 [2]河北省唐山妇幼保健院彩超医学科 [3]河北省开滦总医院彩超医学科 [4]河北省开滦总医院消化科,河北唐山063000

出　　处：《海南医学院学报》2018年第8期833-836,共4页Journal of Hainan Medical University

基　　金：河北省医学科学研究重点课题编号:20160758~~

摘　　要：目的:探讨利拉鲁肽联合二甲双胍对T2DM合并肥胖患者脂代谢及微炎症反应的影响。方法:2016年5月~2017年8月间在本院接受治疗的T2DM合并肥胖患者138例,经随机数表法将其分为对照组、利拉鲁肽组各69例。对照组患者接受二甲双胍治疗、利拉鲁肽组患者接受利拉鲁肽联合二甲双胍治疗,持续3月。对比两组患者胰岛素抵抗指标、胆固醇相关指标、载脂蛋白、炎症介质含量的差异。结果:治疗3月后,利拉鲁肽组血清中胰岛素抵抗相关指标FBG、FINS的水平较对照组低;血清中胆固醇相关指标TC、LDL-C的含量较对照组低,HDL-C的含量较对照组高;血清中载脂蛋白Apo AⅠ、Apo AⅡ的含量较对照组高,Apo CⅡ、Apo CⅢ的含量较对照组低;血清中炎症介质IL-6、IL-17、TNF-α的含量较对照组低。结论:T2DM合并肥胖患者在二甲双胍治疗基础上加入利拉鲁肽联合治疗,可进一步优化机体糖脂代谢并抑制全身微炎症状态。Objective：To investigate the effects of liraglutide combined with metformin on lipid metabolism and microinflammatory response in T2 DM patients with obesity.Methods：138 T2 DM patients with obesity who were treated in the hospital between May 2016 and August 2017 were divided into control group（n=69）and liraglutide group（n=69）by random number table method.Control group received metformin therapy and liraglutide group received liraglutide combined with metformin therapy,which lasted for 3 months.The differences in the levels of insulin resistance indexes,cholesterol-related indexes,apolipoprotein and inflammatory mediators were compared between the two groups.Results：After 3 months of treatment,serum insulin resistance-related indexes FBG and FINS levels of liraglutide group were lower than those of control group;serum cholesterol-related indexes TC and LDL-C contents were lower than those of control group whereas HDL-C content was higher than that of control group;serum apolipoprotein Apo AⅠ and Apo AⅡ contents were higher than those of control group whereas Apo CⅡ and Apo CⅢ contents were lower than those of control group;serum inflammatory mediators IL-6,IL-17 and TNF-αcontents were lower than those of control group.Conclusion：Metformin combined with liraglutide therapy can further optimize the glycolipid metabolism and inhibit the micro-inflammatory state in T2 DM patients with obesity.

关 键 词：T2DM 利拉鲁肽 二甲双胍 脂代谢 微炎症 

分 类 号：R587.1[医药卫生—内分泌]